Johnson & Johnson Comprehensive Income 2010-2024 | JNJ

Johnson & Johnson comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
  • Johnson & Johnson comprehensive income for the quarter ending September 30, 2024 was $-12.522B, a 42.62% increase year-over-year.
  • Johnson & Johnson comprehensive income for 2023 was $-12.527B, a 3.39% decline from 2022.
  • Johnson & Johnson comprehensive income for 2022 was $-12.967B, a 0.7% decline from 2021.
  • Johnson & Johnson comprehensive income for 2021 was $-13.058B, a 14.33% decline from 2020.
Johnson & Johnson Annual Comprehensive Income
(Millions of US $)
2023 $-12,527
2022 $-12,967
2021 $-13,058
2020 $-15,242
2019 $-15,891
2018 $-15,222
2017 $-13,199
2016 $-14,901
2015 $-13,165
2014 $-10,722
2013 $-2,860
2012 $-5,810
2011 $-5,632
2010 $-3,531
2009 $-3,058
Johnson & Johnson Quarterly Comprehensive Income
(Millions of US $)
2024-09-30 $-12,522
2024-06-30 $-11,253
2024-03-31 $-10,768
2023-12-31 $-12,527
2023-09-30 $-8,780
2023-06-30 $-13,135
2023-03-31 $-12,626
2022-12-31 $-12,967
2022-09-30 $-15,292
2022-06-30 $-13,843
2022-03-31 $-13,757
2021-12-31 $-13,058
2021-09-30 $-15,415
2021-06-30 $-15,100
2021-03-31 $-15,328
2020-12-31 $-15,242
2020-09-30 $-14,938
2020-06-30 $-15,533
2020-03-31 $-16,243
2019-12-31 $-15,891
2019-09-30 $-15,533
2019-06-30 $-14,969
2019-03-31 $-15,517
2018-12-31 $-15,222
2018-09-30 $-14,647
2018-06-30 $-14,777
2018-03-31 $-12,608
2017-12-31 $-13,199
2017-09-30 $-12,747
2017-06-30 $-13,234
2017-03-31 $-14,522
2016-12-31 $-14,901
2016-09-30 $-12,715
2016-06-30 $-12,707
2016-03-31 $-12,391
2015-12-31 $-13,165
2015-09-30 $-12,861
2015-06-30 $-12,054
2015-03-31 $-13,300
2014-12-31 $-10,722
2014-09-30 $-5,382
2014-06-30 $-3,007
2014-03-31 $-2,645
2013-12-31 $-2,860
2013-09-30 $-5,346
2013-06-30 $-6,810
2013-03-31 $-6,689
2012-12-31 $-5,810
2012-09-30 $-4,925
2012-06-30 $-6,204
2012-03-31 $-4,540
2011-12-31 $-5,632
2011-09-30 $-3,068
2011-06-30 $-1,192
2011-03-31 $-2,020
2010-12-31 $-3,531
2010-09-30 $-2,924
2010-06-30 $-5,705
2010-03-31 $-3,837
2009-12-31 $-3,058
2009-09-30 $-2,661
2009-06-30 $-4,481
2009-03-31 $-5,169
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.366B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94